Biogena Group Invest AGWBO:BIO -5.41%66 Net Margin % is 83.48% as of Jan. 2026, which is 14% below its 10-year median of 96.64. GuruFocus rates WBO:BIO with a GF Score™ of 66/100 and a GF Value™ of €3.45 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,951 Consumer Packaged Goods companies, Biogena Group Invest AG ranks better than 98.82% on this metric.
The historical rank and industry rank for Biogena Group Invest AG's Net Margin % or its related term are showing as below:
WBO:BIO'
s Net Margin % Range Over the Past 10 Years
Min: 35.56 Med: 96.64 Max: 222.05
Current: 83.48
WBO:BIO's Net Margin % is ranked better than 98.82% of 1951
companies
in the Consumer Packaged Goods industry
Industry Median: 3.51
vs WBO:BIO: 83.48
Biogena Group Invest AG (WBO:BIO) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Biogena Group Invest AG Net Margin % Related Terms
Biogena Group Invest AG Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Biogena Group Invest AG's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogena Group Invest AG Net Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Biogena Group Invest AG's Net Margin % distribution charts can be found below:
* The bar in red indicates where Biogena Group Invest AG's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogena Group Invest AG (WBO:BIO) has a Net Margin % of 83.48% as of Jan. 2026. Net margin is the ratio of total net income to net sales. View historical data on Biogena Group Invest AG and its competitors. This is 14% below median its historical median of 96.64. Over the past decade, Biogena Group Invest AG's Net Margin % has ranged from 35.56 to 222.05. According to the industry distribution chart, Biogena Group Invest AG ranks #23 out of 1951 companies in the Consumer Packaged Goods industry, placing it in the top 1.2%.
Is Biogena Group Invest AG's Net Margin % too high?
Biogena Group Invest AG's current Net Margin % of 83.48% is 14% below median its 10-year median of 96.64. Over the past 10 years, this metric has ranged from a low of 35.56 to a high of 222.05. The Consumer Packaged Goods industry median Net Margin % is 3.51. Biogena Group Invest AG's value of 83.48% is 2278.3% above this industry median. Based on the distribution chart, Biogena Group Invest AG ranks #23 out of 1951 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Biogena Group Invest AG has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biogena Group Invest AG's Net Margin % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Biogena Group Invest AG ranks #23 out of 1951 companies for Net Margin %. This places Biogena Group Invest AG in the top 1% of its industry — outperforming the majority of peers. The industry median Net Margin % is 3.51. Biogena Group Invest AG's value of 83.48% is 2278.3% above this benchmark. Historically, Biogena Group Invest AG's own Net Margin % has ranged from 35.56 to 222.05 over the past decade. While the company's 10-year median is 96.64 vs. the industry median of 3.51, Biogena Group Invest AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Consumer Packaged Goods company?
The median Net Margin % among Consumer Packaged Goods companies is 3.51, based on 1,951 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biogena Group Invest AG's current Net Margin % of 83.48% is 2278.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Biogena Group Invest AG and its competitors. For the Consumer Packaged Goods industry, the median Net Margin % is 3.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogena Group Invest AG's current Net Margin % is 83.48%, which is 14% below median its own 10-year median of 96.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogena Group Invest AG stock overvalued right now?
Based on GuruFocus' analysis, Biogena Group Invest AG (WBO:BIO) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.45, compared to a current price of €4.20 — trading 21.7% above its estimated fair value. The current Net Margin % is 83.48%, which is 14% below median its 10-year median of 96.64 and 2278.3% above the Consumer Packaged Goods industry median of 3.51. Biogena Group Invest AG's overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Biogena Group Invest AG (WBO:BIO), the current Net Margin % is 83.48% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogena Group Invest AG (WBO:BIO) Overvalued in 2026?
Based on GuruFocus' analysis, Biogena Group Invest AG stock appears to be overvalued.
The current stock price of €4.20 is trading 21.7% above its estimated GF Value™ of €3.45.
GuruFocus considers Biogena Group Invest AG to be Modestly Overvalued.
Key valuation signals for WBO:BIO:
Net Margin %: 83.48% (14% below median its 10-year median of 96.64)
GF Value™: €3.45 vs. price of €4.20 (21.7% above fair value)
Industry Position: 2278.3% above the Consumer Packaged Goods median (#23 of 1951)
No single metric tells the full story. See the WBO:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogena Group Invest AG is a holding company. It is engaged in the development and distribution of products and services in the field of health and nutrition. In particular, the focus is on iron, mineral and osteoporosis product innovations and new integrated solutions in the area of workplace health promotion. Its products include vitamin, mineral, enzymes, medicinal mushrooms, among others.
66GF Score
Get the complete analysis for WBO:BIO
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:BIO has been successfully added to your 